Release Summary

3D Medicines (Sichuan) Co., Ltd. and Suzhou Alphamab Co., Ltd. announced that the U.S. FDA has completed IND review for their drug KN035 and informed the pharmaceutical company of their approval.

Suzhou Alphamab Co., Ltd.